Welcome to the Nature Biotechnology and Nature Reviews Drug Discovery joint Web Focus on Antibacterials.

This Web Focus, supported by AstraZeneca and Wyeth Pharmaceuticals, hosts a collection of News and Views, Research Highlights, Reviews, Research Articles, Perspectives and Commentaries covering the science and business of antibacterial drug R&D. It also includes an online-only NPG library of recent research papers and review content from other NPG journals.



Editorials

Bring the magic back to the bullets

doi:10.1038/nbt1206-1489

Nature Biotechnology 24, 2 (2006)

The end of an era?

doi:10.1038/nrd2223

Nature Reviews Drug Discovery 6, 1 (2007)

Top

News & Analysis

The antibacterial drugs market

doi:10.1038/nrd2226

Nature Reviews Drug Discovery 6, 1 (2007)

Top

News Features

A call to arms

doi:10.1038/nrd2225

Nature Reviews Drug Discovery 6, 1 (2007)

Anti-infective antibodies: finding the path forward

Monya Baker

doi:10.1038/nbt1206-1491

Nature Biotechnology 24, 2 (2006)

Antibiotics au naturel

Cormac Sheridan

doi:10.1038/nbt1206-1494

Nature Biotechnology 24, 2 (2006)

Top

Commentaries

Prospects for plant-derived antibacterials

Kim Lewis and Frederick M Ausubel

doi:10.1038/nbt1206-1504

Nature Biotechnology 24, 2 (2006)

Antibiotics — an investment worth making?

Ralph E Christoffersen

doi:10.1038/nbt1206-1512

Nature Biotechnology 24, 2 (2006)

Reinventing phage therapy: are the parts greater than the sum?

Vincent A Fischetti, Daniel Nelson and Raymond Schuch

doi:10.1038/nbt1206-1508

Nature Biotechnology 24, 2 (2006)

Moving goalposts - regulatory oversight of antibacterial drugs

Randall Brenner, Evelyn Ellis Grosse and Roger Echols

doi:10.1038/nbt1206-1515

Nature Biotechnology 24, 2 (2006)

Antibacterial discovery and development - the failure of success?

Prabhavathi Fernandes

doi:10.1038/nbt1206-1497

Nature Biotechnology 24, 2 (2006)

Top

Features

The business of developing antibacterials

Jeffrey L Fox

doi:10.1038/nbt1206-1521

Nature Biotechnology 24, 2 (2006)

Where have all the antibiotic patents gone?

Martin L Katz, Lisa V Mueller, Mark Polyakov and Steven F Weinstock

doi:10.1038/nbt1206-1529

Nature Biotechnology 24, 2 (2006)

Top

Research Highlights

Riboswitching off bacterial growth

Joanna Owens

doi:10.1038/nrd2235

Nature Reviews Drug Discovery 6, 1 (2007)

Top

Reviews

Drugs for bad bugs: confronting the challenges of antibacterial drug discovery

David J. Payne, Michael N. Gwynn, David J. Holmes and David L. Pompliano

doi:10.1038/nrd2201

Nature Reviews Drug Discovery advance online publication, 8 December 2006

Multi-targeting by monotherapeutic antibacterials

Lynn L. Silver

doi:10.1038/nrd2202

Nature Reviews Drug Discovery advance online publication, 8 December 2006

Waltzing transporters and 'the dance macabre' between humans and bacteria

Olga Lomovskaya, Helen I. Zgurskaya, Maxim Totrov and William J. Watkins

doi:10.1038/nrd2200

Nature Reviews Drug Discovery advance online publication, 8 December 2006

Molecular engineering approaches to peptide, polyketide and other antibiotics

Richard H Baltz

doi:10.1038/nbt1265

Nature Biotechnology 24, 813-819 (2006)

New antibiotics from bacterial natural products

Jon Clardy, Michael A Fischbach and Christopher T Walsh

doi:10.1038/nbt1266

Nature Biotechnology 24, 820-828 (2006)

Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies

Robert E W Hancock and Hans-Georg Sahl

doi:10.1038/nbt1267

Nature Biotechnology 24, 820-828 (2006)

Riboswitches as antibacterial drug targets

Kenneth F Blount and Ronald R Breaker

doi:10.1038/nbt1268

Nature Biotechnology 24, 820-828 (2006)

Top